GAAD – Clinical Value of Diagnostics https://clinicalvalue.com Fri, 02 May 2025 07:12:10 +0000 en-US hourly 1 https://wordpress.org/?v=6.6.3 https://i0.wp.com/clinicalvalue.com/wp-content/uploads/2023/01/apple-touch-icon.png?fit=32%2C32&ssl=1 GAAD – Clinical Value of Diagnostics https://clinicalvalue.com 32 32 225041835 Early-stage hepatocellular carcinoma screening in patients with chronic hepatitis B in China: a cost–effectiveness analysis https://clinicalvalue.com/gaad-hecon-china-early-liver-cancer/ Tue, 05 Mar 2024 05:03:08 +0000 https://clinicalvalue.com/?p=8092 ...

The post Early-stage hepatocellular carcinoma screening in patients with chronic hepatitis B in China: a cost–effectiveness analysis appeared first on Clinical Value of Diagnostics.

]]>

Quick Summary

The recently published Chinese standards for the diagnosis and treatment of primary liver cancer [1] mention various screening strategies, including abdominal ultrasonography (US), serological tests such as alpha-fetoprotein (AFP) and protein induced by vitamin K absence/antagonist-II (PIVKA-II).

However, combined screening strategies may be associated with increased costs. The Chinese guidelines [2] highlight that there is a lack of health economic evaluations and evidence on the cost–effectiveness of different liver cancer screening strategies.

This study aims to compare the cost-effectiveness of seven screening strategies:

  1. US
  2. AFP
  3. PIVKA-II
  4. AFP+US
  5. AFP+PIVKA-II
  6. GAAD
  7. GAAD+US

This was done by developing a health economic model from the Chinese healthcare system perspective to identify the most cost-effective strategy for early detection of liver cancer in patients with chronic hepatitis B in China.

Access the full publication

The post Early-stage hepatocellular carcinoma screening in patients with chronic hepatitis B in China: a cost–effectiveness analysis appeared first on Clinical Value of Diagnostics.

]]> 8092 HCC Patient Journey and biomarkers’ roles in the HCC management https://clinicalvalue.com/event/hcc-biomarkers-patient-journey-management/ Tue, 03 Jan 2023 13:55:25 +0000 http://apac-clinicalvalue-prod-lb-800083143.ap-southeast-1.elb.amazonaws.com/?post_type=event&p=6397 Detection of HCC at early stages remains a challenge, with less than 20% of patients being diagnosed at an early stage, when they can benefit from potentially curative therapies(1). In this presentation, Prof. Tawesak Tanwandee discusses the role of tumour markers for early diagnosis of HCC, as well as prognosis and response to treatment. ...

The post HCC Patient Journey and biomarkers’ roles in the HCC management appeared first on Clinical Value of Diagnostics.

]]> The post HCC Patient Journey and biomarkers’ roles in the HCC management appeared first on Clinical Value of Diagnostics.

]]> 6397 GAAD Archives - Clinical Value of Diagnostics adult A comparative analysis of Elecsys GALAD and Elecsys GAAD score to detect early-stage hepatocellular carcinoma in an international cohort https://clinicalvalue.com/gaad-vs-galad-early-detection-hepatocellular-carcinoma/ Thu, 08 Dec 2022 16:18:09 +0000 http://apac-clinicalvalue-prod-lb-800083143.ap-southeast-1.elb.amazonaws.com/?p=6214 This study compared the clinical performance of the Elecsys GALAD (gender [sex], age, alpha-fetoprotein [AFP] Lens culinaris agglutinin-reactive fraction of AFP [AFP-L3] and protein-induced by vitamin K absence-II [PIVKA-II]) and Elecsys GAAD (gender [sex], age, AFP and PIVKA-II) algorithms in differentiating hepatocellular carcinoma and benign chronic liver disease.
Chan HLY, Vogel A, Berg T, De Toni EN, Kudo M, Trojan J, Malinowsky K, Findeisen P, Klein HG, Hegel JK, Schöning W, Kröniger K, Madin K, Sharma A, Piratvisuth T
...

The post A comparative analysis of Elecsys GALAD and Elecsys GAAD score to detect early-stage hepatocellular carcinoma in an international cohort appeared first on Clinical Value of Diagnostics.

]]>

The post A comparative analysis of Elecsys GALAD and Elecsys GAAD score to detect early-stage hepatocellular carcinoma in an international cohort appeared first on Clinical Value of Diagnostics.

]]> 6214